{
  "_metadata": {
    "version": "2.1",
    "ticker": "ARGX",
    "asset_name": "Empasiprubart",
    "extraction_date": "2026-02-11",
    "source_id": "argx_corporate_2026"
  },
  "asset": {
    "name": "Empasiprubart",
    "company": "argenx SE",
    "ticker": "ARGX",
    "stage": "Phase 3 (MMN) / PoC (CIDP, AMR, Scleroderma, AIE, DGF, ALS, SMA)",
    "modality": "Antibody (C2 sweeping antibody)",
    "ownership": null,
    "one_liner": "Empasiprubart is a potent C2 complement sweeping antibody with sustained grip strength improvement in MMN Phase 2, heading into its first Phase 3 readout in a market expected to exceed $1B by 2030."
  },
  "target": {
    "name": "C2",
    "full_name": "Complement Component 2",
    "class": "Complement pathway protein",
    "pathway": "Complement cascade (classical and lectin pathways)",
    "biology": {
      "simple_explanation": "C2 is a key component of the complement system, part of the immune system's attack machinery. By sweeping C2 from the blood, empasiprubart blocks the complement cascade that damages nerves and tissues in autoimmune diseases.",
      "pathway_detail": null,
      "downstream_effects": null
    },
    "why_good_target": {
      "clinical_validation": "ARDA Phase 2 showed sustained grip strength improvement in MMN through 64 weeks in OLE",
      "genetic_validation": {
        "gain_of_function": null,
        "loss_of_function": null
      },
      "source": {
        "id": "argx_corporate_2026",
        "slide": 19,
        "verified": false
      }
    }
  },
  "mechanism": {
    "type": "C2 sweeping antibody",
    "how_it_works": "Potent sweeping antibody that binds C2 and accelerates its clearance, inhibiting classical and lectin complement pathways",
    "differentiation": "Sweeping antibody technology; first targeted treatment being developed in MMN",
    "source": {
      "id": "argx_corporate_2026",
      "slide": 20,
      "verified": false
    }
  },
  "regulatory": {
    "designations": null,
    "planned_pathway": {
      "type": null,
      "surrogate_endpoint": null,
      "source": {
        "id": "argx_corporate_2026",
        "slide": null,
        "verified": false
      }
    }
  },
  "partnership": {
    "_note": "No partnership information provided",
    "partner": null,
    "territory": null,
    "economics": null
  },
  "pharmacology": {
    "pk_parameters": {
      "half_life": {
        "value": null,
        "population": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": null,
          "verified": false
        }
      },
      "cmax": {
        "value": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": null,
          "verified": false
        }
      },
      "auc": {
        "value": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": null,
          "verified": false
        }
      },
      "tmax": {
        "value": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": null,
          "verified": false
        }
      },
      "bioavailability": {
        "value": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": null,
          "verified": false
        }
      },
      "volume_of_distribution": {
        "value": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": null,
          "verified": false
        }
      }
    },
    "dose_response": {
      "doses_tested": null,
      "dose_rationale": null,
      "exposure_response": null,
      "recommended_dose": {
        "dose": null,
        "rationale": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": null,
          "verified": false
        }
      },
      "by_dose": null
    },
    "target_engagement": {
      "metric": null,
      "by_dose": null
    },
    "pk_summary": null
  },
  "indications": {
    "lead": {
      "name": "MMN (Multifocal Motor Neuropathy)",
      "patient_population": "12K patients across key markets",
      "current_penetration": "Zero targeted treatments available",
      "rationale": "High unmet need; 40% initially misdiagnosed; 60% progression despite treatment; severe disability in 20%",
      "source": {
        "id": "argx_corporate_2026",
        "slide": 18,
        "verified": false
      }
    },
    "expansion": [
      {
        "name": "CIDP",
        "stage": "Phase 3 (readout 2H 2027)",
        "rationale": "Co-positioning with VYVGART",
        "source": {
          "id": "argx_corporate_2026",
          "slide": 24,
          "verified": false
        }
      },
      {
        "name": "AMR",
        "stage": "PoC",
        "rationale": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": 23,
          "verified": false
        }
      },
      {
        "name": "Scleroderma",
        "stage": "PoC",
        "rationale": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": 23,
          "verified": false
        }
      },
      {
        "name": "AIE",
        "stage": "PoC",
        "rationale": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": 23,
          "verified": false
        }
      },
      {
        "name": "DGF",
        "stage": "PoC",
        "rationale": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": 23,
          "verified": false
        }
      },
      {
        "name": "ALS",
        "stage": "PoC",
        "rationale": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": 23,
          "verified": false
        }
      },
      {
        "name": "SMA",
        "stage": "PoC",
        "rationale": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": 23,
          "verified": false
        }
      }
    ]
  },
  "clinical_data": {
    "trials": [
      {
        "name": "ARDA Phase 2",
        "nct_id": null,
        "phase": "Phase 2",
        "status": "Completed",
        "design": "Randomized, placebo-controlled (2 cohorts)",
        "enrollment": "Cohort 1: EMP N=18, PBO N=9; Cohort 2: EMP N=18, PBO N=9 (at baseline)",
        "arms": [
          {
            "name": "EMP-EMP Cohort 1",
            "dose": null,
            "n": 18
          },
          {
            "name": "EMP-EMP Cohort 2",
            "dose": null,
            "n": 18
          },
          {
            "name": "PBO-EMP Cohort 1",
            "dose": null,
            "n": 9
          },
          {
            "name": "PBO-EMP Cohort 2",
            "dose": null,
            "n": 9
          }
        ],
        "primary_endpoint": {
          "name": "Grip strength change from baseline (kPA)",
          "definition": "Change from baseline in grip strength measured in kiloPascals",
          "result": "Grip strength curves shown (slide 19): EMP-EMP Cohort 2 ~20-25 kPA improvement at week 16; EMP-EMP Cohort 1 ~15 kPA at week 16; PBO-EMP Cohort 1 ~2-5 kPA; PBO-EMP Cohort 2 ~0 kPA. Numeric values estimated from graph. No p-values provided.",
          "source": {
            "id": "argx_corporate_2026",
            "slide": 19,
            "verified": false
          }
        },
        "secondary_endpoints": null,
        "biomarkers": null,
        "safety": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": 19,
          "verified": false
        }
      },
      {
        "name": "ARDA+ Open Label Extension",
        "nct_id": null,
        "phase": "Phase 2 OLE",
        "status": "Ongoing",
        "design": "Open-label extension",
        "enrollment": "EMP-EMP Cohort 1: 15 at wk64; Cohort 2: 12 at wk64; PBO-EMP Cohort 1: 5; Cohort 2: 6",
        "arms": null,
        "primary_endpoint": {
          "name": "Grip strength change from baseline (kPA) \u2014 sustained",
          "definition": null,
          "result": "Sustained improvement through 64 weeks: EMP-EMP Cohort 2 reached ~35-40 kPA; Cohort 1 ~20 kPA at week 64. PBO-EMP cohorts showed lower improvements after crossover (~15 kPA Cohort 1, ~5 kPA Cohort 2). Numeric values estimated from graph.",
          "source": {
            "id": "argx_corporate_2026",
            "slide": 19,
            "verified": false
          }
        },
        "secondary_endpoints": null,
        "biomarkers": null,
        "safety": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": 19,
          "verified": false
        }
      },
      {
        "name": "EMPASSION",
        "nct_id": null,
        "phase": "Phase 3",
        "status": "Readout expected 4Q 2026",
        "design": "Head-to-head trial vs IVIg",
        "enrollment": null,
        "arms": null,
        "primary_endpoint": {
          "name": null,
          "definition": null,
          "result": null,
          "source": {
            "id": "argx_corporate_2026",
            "slide": 26,
            "verified": false
          }
        },
        "secondary_endpoints": null,
        "biomarkers": null,
        "safety": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": 26,
          "verified": false
        }
      },
      {
        "name": "CIDP Phase 3",
        "nct_id": null,
        "phase": "Phase 3",
        "status": "Readout expected 2H 2027",
        "design": null,
        "enrollment": null,
        "arms": null,
        "primary_endpoint": {
          "name": null,
          "definition": null,
          "result": null,
          "source": {
            "id": "argx_corporate_2026",
            "slide": 24,
            "verified": false
          }
        },
        "secondary_endpoints": null,
        "biomarkers": null,
        "safety": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": 24,
          "verified": false
        }
      },
      {
        "name": "ADAPT Forward (combination: efgartigimod + empasiprubart)",
        "nct_id": null,
        "phase": "Combination study",
        "status": "Exploring",
        "design": "Combination of efgartigimod and empasiprubart in MG",
        "enrollment": null,
        "arms": null,
        "primary_endpoint": {
          "name": null,
          "definition": null,
          "result": null,
          "source": {
            "id": "argx_corporate_2026",
            "slide": 16,
            "verified": false
          }
        },
        "secondary_endpoints": null,
        "biomarkers": null,
        "safety": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": 16,
          "verified": false
        }
      }
    ]
  },
  "differentiation_claims": [
    {
      "claim": "Zero targeted treatments currently available in MMN",
      "evidence_level": "management_claim",
      "caveat": "Current SOC is IVIg",
      "source": {
        "id": "argx_corporate_2026",
        "slide": 18,
        "verified": false
      }
    },
    {
      "claim": "Sustained grip strength improvement through 64 weeks in OLE",
      "evidence_level": "cross_trial",
      "caveat": "OLE data; small N (12-15 at week 64); no placebo comparison in OLE",
      "source": {
        "id": "argx_corporate_2026",
        "slide": 19,
        "verified": false
      }
    }
  ],
  "competitive_landscape": {
    "competitors": [
      {
        "drug": "IVIg",
        "company": "Multiple (PPTA, Takeda, CSL)",
        "stage": "Approved / SOC",
        "mechanism": "Immunoglobulin replacement",
        "key_data": null,
        "limitation": "60% progression despite treatment; not targeted",
        "differentiation_vs_us": "EMPASSION Phase 3 is head-to-head vs IVIg"
      }
    ]
  },
  "ip_landscape": {
    "composition_of_matter": {
      "patent_expiry": null,
      "source": {
        "id": "argx_corporate_2026",
        "slide": null,
        "verified": false
      }
    },
    "method_of_use": {
      "patent_expiry": null,
      "source": {
        "id": "argx_corporate_2026",
        "slide": null,
        "verified": false
      }
    },
    "regulatory_exclusivity": {
      "type": null,
      "expiry": null
    },
    "freedom_to_operate": null
  },
  "market_opportunity": {
    "mmn_patients_key_markets": "12K patients across key markets",
    "mmn_market_current": "$750-800M (PPTA, Takeda, CSL, argenx analysis)",
    "mmn_market_2030": "Expected to grow beyond $1B by 2030",
    "mmn_unmet_need": "60% of patients progress despite treatment. 40% initially misdiagnosed (often as ALS). Severe disability in 20%. Zero targeted treatments currently available.",
    "phase2_evidence": "ARDA Phase 2 showed sustained improved grip strength in MMN (continued improvement in open-label extension)",
    "source": {
      "id": "argx_jpm_2026_slides",
      "slide": 18,
      "verified": true
    }
  },
  "catalysts": [
    {
      "event": "EMPASSION Phase 3 MMN readout",
      "timing": "4Q 2026",
      "importance": "critical",
      "what_to_watch": "Head-to-head vs IVIg. First targeted treatment in MMN. Supported by ARDA Phase 2 showing sustained grip strength improvement."
    },
    {
      "event": "EMVIGORATE + EMNERGIZE Phase 3 CIDP readout",
      "timing": "2H 2027",
      "importance": "high",
      "what_to_watch": "Co-positioning with VYVGART in CIDP. Expanding addressable market."
    },
    {
      "event": "VARVARA Phase 2 DGF decision",
      "timing": "Mid-2026",
      "importance": "medium",
      "what_to_watch": "52-week efficacy analysis to inform development decision in delayed graft function."
    },
    {
      "event": "ADAPT-Forward combination with efgartigimod in AChR+ gMG",
      "timing": "Ongoing",
      "importance": "medium",
      "what_to_watch": "Exploring empasiprubart as add-on therapy to efgartigimod for deeper efficacy."
    }
  ],
  "investment_analysis": {
    "probability_of_success": null,
    "key_risks": [
      "Head-to-head vs IVIg is a high bar",
      "Small Phase 2 sample sizes",
      "Graph-only efficacy data (no formal statistics provided)"
    ],
    "bull_case": [
      {
        "thesis": "First targeted treatment in MMN with >$1B market opportunity",
        "evidence": "Slide 18 market data",
        "confidence": "medium"
      },
      {
        "thesis": "Sustained 64-week grip strength improvement in OLE",
        "evidence": "ARDA+ data (slide 19)",
        "confidence": "medium"
      }
    ],
    "bear_case": [
      {
        "thesis": "Phase 3 head-to-head vs IVIg is challenging design",
        "evidence": "Slide 26 trial description",
        "confidence": "medium"
      },
      {
        "thesis": "Phase 2 N=9-18 per arm; clinical significance of grip strength improvement uncertain",
        "evidence": "Slide 19 sample sizes",
        "confidence": "medium"
      }
    ],
    "key_debates": [
      {
        "question": "Can empasiprubart beat IVIg head-to-head in MMN?",
        "bull_view": "IVIg only manages disease; 60% still progress; empasiprubart targets root cause",
        "bear_view": "IVIg is a proven therapy; head-to-head superiority is a high bar",
        "what_resolves_it": "EMPASSION Phase 3 readout 4Q 2026"
      }
    ]
  },
  "_extraction_quality": {
    "completeness_score": "medium",
    "missing_critical_fields": [
      "PK parameters",
      "Dosing regimen",
      "Safety data",
      "Formal statistical results from Phase 2",
      "NCT IDs",
      "IP/patents",
      "Regulatory designations"
    ],
    "recommended_supplementary_sources": [
      "ARDA Phase 2 publication for full statistical analysis",
      "ClinicalTrials.gov for EMPASSION trial details",
      "ECTRIMS/AAN presentations for full MMN data"
    ]
  }
}